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Abstract Purpose: Germline mutations in either BRCA1
or BRCA2 genes are responsible for the majority of
hereditary breast and ovarian cancers. At present, over
thousand distinct BRCA1 and BRCA2 mutations have
been identified. Specific mutations are found to be
common within particular populations, resulting from
genetic founder effects. To investigate the contribution
of germline mutations in these two genes to inherited
breast cancer in Iran, we performed BRCA1/BRCA2
mutation analyses in ten Iranian high risk breast cancer
families. This is the first study analysing the complete
coding sequences of both genes that concerns the Iranian
population. Methods: BRCA1/BRCA2 mutation detec-
tion included sequencing of the coding and the 3¢ and 5¢
untranslated regions. To detect large genomic re-
arrangements in the BRCA1 gene semi-quantitative
multiplex PCR was performed. Results: Two pathogenic
mutations in the BRCA2 gene were detected: a novel
deletion c.4415_4418delAGAA and a previously de-
scribed insertion c.6033_6034insGT. In addition, one
intronic variation g.5075–53C>T and a deletion/inser-
tion g.*381_389del9ins29 in the 3¢ untranslated region of
BRCA1 were found in two of the investigated families.
Both sequence alterations were absent in an age matched
Iranian control group. The BRCA2 homozygous varia-
tion p.N372H, previously associated with an increased
risk for developing breast cancer, was not identified in
this study. We did not detect large genomic rearrange-
ments in BRCA1 in patients tested negatively for disease
causing mutations in both genes by standard sequencing.
Conclusions: At present, the BRCA2 mutations
c.4415_4418delAGAA and c.6033_6034insGT have not
been identified in any investigated population except the
Iranian. Whether both mutations are specific for the
Iranian population or a special subgroup remains to be
investigated in larger studies. The absence of BRCA1
mutations in the analysed families may suggest that
penetrance or prevalence of BRCA1 mutations may be
lower in Iran.
Keywords Breast cancer Æ Ovarian cancer Æ BRCA2 Æ
BRCA1 Æ Mutation Æ Unclassified variants Æ Iran
Introduction
Worldwide, breast cancer is one of the most frequent
malignancies in females. Within the Iranian population,
neoplasms of the oesophagus and cancers of the breast
and cervix are leading malignancies among women
(Mosavi-Jarrahi et al. 2001). The majority of breast
cancer cases appear sporadically. About 5–10% of
breast cancer affected women have a familiar back-
ground for the disease. To date, family history remains
one of the strongest predictors of breast cancer risk
(Mehdipour et al. 2003). Therefore, attention has been
focused on the role of the breast cancer susceptibility
genes BRCA1 (MIM# 113705) and BRCA2 (MIM#
600185). Germline mutations in either of these genes are
responsible for a lifetime risk of breast cancer (82%) and
ovarian cancers (54% for BRCA1 and 23% for BRCA2
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mutation carriers; King et al. 2003). At present, over
thousand distinct BRCA1 and BRCA2 mutations,
polymorphisms and unclassified sequence variants have
been identified [The Breast Cancer Information Core
(BIC) database, january 2005]. In addition, recent stu-
dies have revealed large rearrangements within BRCA1
resulting from homologous recombination events (Gad
et al. 2002; The BRCA1 Exon 13 Duplication Screening
Group 2000; Unger et al. 2000). Specific BRCA1/2 mu-
tations are found to be common within particular po-
pulations, resulting from genetic founder effects
(Neuhausen 2000). To date, only a small number of
germline mutations in BRCA1 and BRCA2 have been
identified in women with early-onset breast cancer with
or without a family history of the disease within the
Iranian population (Ghaderi et al. 2001; Yassaee et al.
2002). To investigate the contribution of germline mu-
tations of these genes to inherited breast cancer in Iran,
we have focused our interest on ten Iranian high risk
breast cancer families with three or more individuals
affected with the disease. The BRCA1/2 mutation
screening was performed by direct sequencing. Fur-
thermore, large rearrangements within BRCA1 were
searched for using semi-quantitative multiplex PCR as
described previously (Hofmann et al. 2002).
Materials and methods
Study subjects
Based on the following criteria, ten unrelated Iranian
high risk breast or breast–ovarian cancer families were
included in this study: at least three breast and/or
ovarian cancer cases as first-degree relatives, multiple
cases as first, second and distant relatives in the same
lineage, bilateral breast cancer, occurrence of breast
and/or ovarian cancer with onset under the age of
50 years (Table 1). Blood samples from these families
were collected in the Department of Surgery, Day hos-
pital and Cancer Institute, Tehran University of Medical
Sciences, in Tehran. Information concerning the pedi-
grees were gathered on the basis of multiple interviews
and DNA samples were extracted from peripheral blood
lymphocytes using the standard phenol-chloroform
procedure in the Department of Medical Genetics,
Tehran University of Medical Sciences. DNA samples of
20 unrelated healthy female Iranian individuals served as
an age matched control group and were a gift from the
Iranian Human Mutation Gene Bank (Najmabadi et al.
2003).
Table 1 Characterization of the Iranian breast cancer families
Family Number of breast cancer cases
(age at diagnosis or age at death)
Number of
bilateral breast
cancer cases
Additional cancer cases
among the families
(age at diagnosis or age at death)
BRCA1/2
sequence
changea
I 8 (?, 30, 44, 48, 48, 48, 65, 70) –
Liver (51), colon (40),
prostate (57), leukaemia (60, 16)
–
II 8 (25, 30, 35, 36, 50, 53, 56, 60) – Gastric (27) –
III 5 (?, 40, 40, 43, 60) 2 – BRCA1:
g.*381_389del9
ins29
IV 3 (30, 40, 45) – – –
V 5 (37, 38, 42, 42, 44) – Leukaemia (3), ovary (70), brain (38),
uterus (65), lung (80),
prostate (55), brain (40), colon (?)
–
VI 8 Maternal (?, 31, 35, 50, 56, 63, 64, 70)
and 3 paternal (26, 45, 60)
– Paternal: leukaemia (80, 40),
uterus (62, 39),
larynx (60), brain (39), lung (57)
maternal: ovary (28),
–
VII 12 Paternal (?, 25, 25, 27, 30, 37, 50, 50, 58, 58,
62, 65, 67)
and 1 maternal (60)
1 Paternal: uterus (76, 54, 56, 45),
stomach (52),
leukaemia (58, ?, ?)
maternal: bladder (60), lung (60),
uterus (70)
BRCA1:
g.5075–53C>T
VIII 4 Maternal (42, 58, 62, 64) and 2 paternal (50, 62) – Maternal: pancreas (54), thyroid
gland (56),
uterus (80)
–
IX 5(?, 27, 32, 33, 60) – Liver (62) BRCA2:
c.6033_6034
insGT
X 3 (37, 39, 50) – Unknown (79, ?) BRCA2:
c.4415_4418del
AGAA
aName of sequence alteration according to the nomenclature recommendations by den Dunnen and Antonarakis (http://www.dmd.nl/
mutnomen.html 2004; den Dunnen and Antonarakis 2001)
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Direct sequencing
PCR products of all exons and the flanking intronic
regions and the 5¢ and 3¢ untranslated regions (UTR)
of BRCA1 and the 5¢ UTR of BRCA2 were analysed
using the Applied Biosystem BigDye Terminator v.3.0
Ready Reaction Cycle Seqkit and the Applied Bio-
system ABI 377 sequencer in the Department of Tu-
mor Genetics, Max Delbru¨ck Center, Berlin, according
to the manufacturer’s instructions. The sequences of
the primers used may be obtained from the corre-
sponding author upon request.
Semi-quantitative fluorescent multiplex PCR
To detect large rearrangements, the protein-coding
exons of the BRCA1 gene and the 5¢ UTR containing a
promotor fragment of BRCA1 were amplified by semi-
quantitative PCR from genomic DNA of the probands,
as described by Hofmann et al. (2003).
Results
Frameshift mutations were found in the BRCA2 gene of
two Iranian breast cancer families leading to a pre-
mature stop codon (Tables 1, 2). An insertion of GT at
nucleotide position 6034 in exon 11 (BRCA2
c.6033_6034insGT, corresponding to the traditional
nomenclature 6262insGT) results in a translation stop at
codon 2040 in family IX (Fig. 1).
A deletion of AGAA at nucleotide-position 4415 in
exon 11 (BRCA2 c.4415_4418delAGAA, corresponding
to the traditional nomenclature 4643delAGAA) leads to
a premature stop codon at position 1477 in family X
(Fig. 2).
Table 2 Sequence variations in
BRCA1 and BRCA2 among the
Iranian breast cancer families
UV unclassified variant,
FS Frame-shift
aName of sequence alteration
according to the nomenclature
recommendations by den
Dunnen and Antonarakis
(http://www.dmd.nl/
mutnomen.html 2004; den
Dunnen and Antonarakis 2001)
1Correlating BRCA1 poly-
morphisms (P) defining the
most frequent haplotype after
the wild type (wt)
2, 3Additional more rare
BRCA1 haplotypes
BRCA1/2 alterationa Exon
(intron)
Effect on aminoacid Mutation
type
Allele frequency
(in investigated
Iranian families)
BRCA1:
g.-1075C>G (1a) – P1,3 7/20 (35%)
g.-235A>G (1b) – P1 6/20 (30%)
g.-134T>C (1b) – P1 6/20 (30%)
g.442–34C>T (7) – P2 4/20 (20%)
g.548–58delT (8) – P1 6/20 (30%)
c.2077G>A 11 p.Asp693Asn P 1/20 (5%)
c.2082C>T 11 p.Ser694Ser P1 6/20 (30%)
c.2311T>C 11 p.Leu771Leu P1 6/20 (30%)
c.2612C>T 11 p.Pro871Leu P1, 3 7/20 (35%)
c.3113A>G 11 p.Glu1038Gly P1 6/20 (30%)
c.3119G>A 11 p.Ser1040Asn P2 2/20 (10%)
c.3548A>G 11 p.Lys1183Arg P1 6/20 (30%)
c.4308T>C 13 p.Ser1436Ser P1 6/20 (30%)
c.4837A>G 16 p.Ser1613Gly P1 6/20 (30%)
g.4987–68A>G (16) – P1 6/20 (30%)
g.4987–92A>G (16) – P1 6/20 (30%)
g.5075–53C>T (17) – UV 1/20 (5%)
g.5152+66G>A (18) – P1 6/20 (30%)
g.*381_389del9ins29 24 – UV 1/20 (5%)
g.*421G>T 24 – P1 6/20 (30%)
g.*1286C>T 24 – P1 6/20 (30%)
BRCA2:
g.-1235G>A - – P 1/20 (5%)
g.-26G>A 2 – P 4/20 (20%)
g.681+56C>T (8) – P 2/20 (10%)
c.865A>C 10 p.Asn289His P 3/20 (15%)
c.1114A>C 10 p.Asn372His P 3/20 (15%)
c.1365A>G 10 p.Ser455Ser P 2/20 (10%)
c.2229T>C 11 p.His743His P 2/20 (10%)
c.2971A>G 11 p.Asn991Asp P 2/20 (10%)
c.3396A>G 11 p.Lys1132Lys P 5/20 (25%)
c.3516G>A 11 p.Ser1172Ser P 1/20 (5%)
c.3807T>C 11 p.Val1269Val P 8/20 (40%)
c.4415_4418delAGAA 11 p.Lys1472fsX5 FS 1/20 (5%)
c.5529A>C 11 p.Ala1843Ala P 1/20 (5%)
c.6033_6034insGT 11 p.Ser2012fsX28 FS 1/20 (5%)
c.7242A>G 14 p.Ser2414Ser P 4/20 (20%)
g.7435+53C>T (14) – P 2/20 (10%)
g.7806–14T>C (16) – P 8/20 (40%)
g.8755–66T>C (21) – P 8/20 (40%)
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Sequence analysis of BRCA1 showed a nucleotide
change in intron 17 (g.5075–53C>T, corresponding to
the traditional nomenclature IVS17–53C>T) in family
VII (Fig. 3). Segregation analysis could not be per-
formed because DNA of affected and unaffected re-
latives was not available. However, g.5075–53C>T did
not appear in the analysed alleles of the 20 healthy fe-
male control individuals from the Iranian population.
Furthermore, the alteration g.*381_389del9ins29 in the
3’UTR of BRCA1 was identified in family III (Fig. 4).
This sequence change did not show complete segregation
with the disease in this family. This alteration was absent
in the healthy mother, as well as in two breast cancer
affected sisters of the proband. Another healthy sister
was also a carrier of this variation.
In this study, many alterations, previously described
as polymorphisms (BIC 2005), have been identified in
BRCA1 and BRCA2 (Table 2). In addition, certain
polymorphisms in BRCA1 were found to correlate with
each other (Table 2). No large rearrangements in
BRCA1 were detected using semi-quantitative fluor-
escent multiplex PCR.
Discussion
Since the identification of the breast and ovarian cancer
susceptibility genes BRCA1 and BRCA2, the Caucasian
populations in North America, Europe, Israel and
Australia have been investigated for germline muta-
tions in both genes using different PCR-based mutation
detection methods. Few studies concerning BRCA1 and
BRCA2 alterations in the Iranian population have been
published: In a study performed by Yassaee and col-
legues, 83 early-onset breast cancer patients from
Tehran were investigated (Yassaee et al. 2002). Based
on this study, the prevalence of BRCA1/2 mutations
among early-onset breast cancer patients (<45 years)
with or without a family history for the disease is
thought to be approximately 6%. Ghaderi and colle-
gues performed BRCA1 mutation screening in a study
comprising 80 patients with breast cancer with a
median age of 42 years at onset of the disease from
Shiraz, Iran (Ghaderi et al. 2001). Only two of the
patients had a family history of breast and/or ovarian
cancer. Analysis of exons 2, 20 and 11 of BRCA1 and
exons 10 and 11 of BRCA2 has been restricted to a
single Iranian family with hereditary breast and ovar-
ian cancer syndrome (Moslehi et al. 2003). In this
family a novel nonsense mutation in BRCA1 was
identified (G2031T, using the traditional nomen-
clature).
In our study, both BRCA1 and BRCA2 genes were
screened in ten high risk breast cancer families of non-
jewish origin. Two of the investigated families were
found to inherit disease-causing frameshift mutations
(Table 1). Both mutations, c.4415_4418delAGAA and
c.6033_6034insGT, were located in exon 11 of
BRCA2. Alterations in this region confer a higher risk
for developing ovarian cancer (OCCR) (Thompson
et al. 2001). In contrast, the pedigrees of the families
involved did not show cases of ovarian cancer. In a
Fig. 1 a Pedigree of family IX. b Electropherogramm of the
mutation BRCA2 c.6033_6034insGT
Fig. 2 a Pedigree of family X. b Electropherogramm of the
detected mutation BRCA2 c.4415_4418delAGAA
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study conducted on Spanish breast/ovarian cancer
patients, no association with mutations situated in the
ovarian cancer cluster region (OCCR) of BRCA2, but
rather an association between ovarian cancer
and mutations localized in the 5¢ end of BRCA1 was
found (Diez et al. 2003). Whether additional en-
vironmental factors or other genetic modifiers may
influence the development of certain phenotypes re-
mains unclear.
To our knowledge, the BRCA2 mutation c.4415_441
8delAGAA is novel (BIC 2005, january). BRCA2
c.6033_6034insGT has been described previously in a
single Iranian woman with early-onset breast cancer
(Yassaee et al. 2002). It remains to be investigated
whether these sequence changes represent isolated cases
or founder mutations in the Iranian population.
The clinical consequences of the intronic BRCA1 se-
quence variation g.5075–53C>T and the 3¢ UTR altera-
tion g.*381_389del9ins29 are unclear. The BRCA1
variation g.5075–53C>Twas found neither in the control
subjects nor in the remaining investigated families. Con-
cerning the alteration g.*381_389del9ins29 in the 3’UTR
of BRCA1, we conclude that this variation was not causal
for breast cancer occurrence in family III, because of
missing segregation with the disease. Investigation of the
control group did not show this variant.
In this study, many polymorphisms spreading o ut
over the whole gene regions of BRCA1 and BRCA2
have been found. In BRCA1 there is a correlation
between several of the polymorphisms. The strong
correlation could allow certain haplotypes to be de-
fined and this finding can help in understanding the
evolutionary development of variants (Shattuck-Eidens
et al. 1997; Liu and Barker 1999). Whether certain
haplotypes are associated with an increased breast
cancer risk remains unclear. To date, some studies
have found an increased risk of developing breast
cancer in individuals who show homozygous geno-
types for special variants, for instance the BRCA2
p.N372HH genotype (Healey et al. 2000; Goode et al.
2002). Three of our investigated patients show a het-
erozygous genotype (p.N372NH).
Using the sequencing method, we did not find any
frameshift and nonsense mutations leading to a pre-
mature translation stop in BRCA1. In addition, se-
quencing methods are not suitable for detecting large
genomic rearrangements (Unger et al. 2000). Therefore,
the semi-quantitative multiplex PCR method to screen
these patients for large deletions or duplications within
the BRCA1 gene was used in this study. None of the
investigated patients showed a BRCA1 rearrangement.
In summary, two pathogenic mutations in the BRCA2
gene have been detected in this study: c.6033_6034insGT
previously described in a single Iranian woman affected
with breast cancer and a novel c.4415_4418delAGAA
mutation. Whether these alterations are specific for the
Iranian population or for special subgroups remains to be
investigated in larger studies. Interestingly, we did not
detect a disease causing mutation in BRCA1. Penetrance
or prevalence of BRCA1 mutations may be lower in Iran
(Liede and Narod 2002). Whether the remaining eight
Fig. 3 a Pedigree of family VII. b Electropherogramm of the
BRCA1 variation g.5075–53C>T
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investigated high risk breast cancer families carry disease
causing mutations in unknown breast cancer suscept-
ibility genes or in rare modifier genes is still unclear. In-
vestigation of the influence of additional environmental
factors in connection with genetic variants such as poly-
morphisms or special haplotypes are therefore necessary.
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